



Vyndamax in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

RARE DISEASE · ATTR CARDIOMYOPATHY

The clinical situation

Vyndamax (tafamidis) is an oral selective TTR stabiliser FDA-approved for the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalisation. Manufactured by Pfizer. Vyndamax is a once-daily 61 mg soft-gel capsule (bioequivalent to Vyndaqel 80 mg). Pre-treatment workup covers ATTR-CM diagnostic confirmation (PYP scintigraphy or biopsy), TTR genotype for hereditary form, LFTs, and cardiac baseline per FDA labelling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your cardiologist documents ATTR-CM diagnosis via PYP scintigraphy or biopsy, TTR genotype, NYHA class, and Vyndamax rationale.
- 2 Baseline workup.** LFTs, cardiac baseline (echo, NT-proBNP, troponin), ECG per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the first 30-day supply; monthly refill cadence established.

Indicative economics

Reference US cash-pay range: USD 225,000–260,000 per year of Vyndamax (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Pfizer authorised distribution.

Documentation. Physician kit tailored to SFDA review, with ATTR-CM diagnostic confirmation annex. **Logistics.** Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Vyndamax × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/vyndamax-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team